No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
PDSB240517P10000
- 6.20
- 0.000.00%
15min DelayClose Mar 27 10:35 ET
0.00High0.00Low
6.20Open6.20Pre Close0 Volume0 Open Interest10.00Strike Price0.00Turnover0.00%IV12.54%PremiumMay 17, 2024Expiry Date6.49Intrinsic Value100Multiplier7DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type--Delta--Gamma0.58Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- 1D
News
PDS Biotechnology Says Head, Neck Cancer Therapy Met Main Goal in Mid-Stage Study
PDS Biotechnology (PDSB) said late Thursday its experimental therapy to treat a type of head and neck cancer in combination with Merck's Keytruda met the primary study endpoints in a phase 2 clinical
Express News | PDS Biotech's VERSATILE-002 Phase 2 Clinical Trial Met Primary Study Endpoints
Express News | PDS Biotechnology Corp: Plans to Initiate a Pivotal Clinical Trial in 2024 to Advance Its Lead Program in Advanced Head and Neck Squamous Cell Cancers
Express News | PDS Biotech Versatile-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic Hpv16-Positive Head and Neck Cancer
Express News | HC Wainwright & Co. Reiterates Buy on PDS Biotechnology, Maintains $21 Price Target
Express News | Cantor Fitzgerald Reiterates Overweight on PDS Biotechnology
Comments
$PDS Biotechnology(PDSB.US$ PDS Biotech's VERSATILE-002 Phase 2 Clinical Trial Met Primary Study Endpoints
1
$PDS Biotechnology(PDSB.US$
NEWS
PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer
PDS Biotech's VERSATILE-002 Phase 2 clinical trial for first-line recurrent/metastatic HPV16-positive head and neck cancer met primary study endpoints with a 30-month median overall survival, impressive response rates, and a planned Phase 3 trial in 2024. The trial evaluated the combination of Versamune® HPV + KEYT...
NEWS
PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer
PDS Biotech's VERSATILE-002 Phase 2 clinical trial for first-line recurrent/metastatic HPV16-positive head and neck cancer met primary study endpoints with a 30-month median overall survival, impressive response rates, and a planned Phase 3 trial in 2024. The trial evaluated the combination of Versamune® HPV + KEYT...
1
Read more